Cutler Group LP C4 Therapeutics, Inc. Transaction History
Cutler Group LP
- $307 Million
- Q1 2024
A detailed history of Cutler Group LP transactions in C4 Therapeutics, Inc. stock. As of the latest transaction made, Cutler Group LP holds 800 shares of CCCC stock, worth $4,000. This represents 0.0% of its overall portfolio holdings.
Number of Shares
800
Previous 2,600
69.23%
Holding current value
$4,000
Previous $14,000
57.14%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding CCCC
# of Institutions
110Shares Held
49.4MCall Options Held
455KPut Options Held
429K-
State Street Corp Boston, MA7.15MShares$35.8 Million0.0% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT4.33MShares$21.6 Million0.19% of portfolio
-
Commodore Capital LP New York, NY3.41MShares$17.1 Million2.41% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.92MShares$14.6 Million0.0% of portfolio
-
Soleus Capital Management, L.P. Greenwich, CT2.46MShares$12.3 Million1.64% of portfolio
About C4 Therapeutics, Inc.
- Ticker CCCC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 48,913,800
- Market Cap $245M
- Description
- C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting ...